Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323 to treat lung cancer; DFP-17729, DFP-11207, and DFP-14927 for the treatment of solid tumors; and DFP-10825 for peritoneal metastasis. The company was founded in 2010 and is headquartered in Tokushima, Japan.